Komipharm International Past Earnings Performance
Past criteria checks 2/6
Komipharm International has been growing earnings at an average annual rate of 45.7%, while the Pharmaceuticals industry saw earnings growing at 11.5% annually. Revenues have been growing at an average rate of 6.9% per year. Komipharm International's return on equity is 18.3%, and it has net margins of 20.8%.
Key information
45.7%
Earnings growth rate
46.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 11.3% |
| Revenue growth rate | 6.9% |
| Return on equity | 18.3% |
| Net Margin | 20.8% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Impressive Earnings May Not Tell The Whole Story For Komipharm International (KOSDAQ:041960)
Nov 08
Is Komipharm International (KOSDAQ:041960) A Risky Investment?
Mar 27A Look At Komipharm International's (KOSDAQ:041960) Share Price Returns
Feb 26Is Komipharm International Co., Ltd.'s (KOSDAQ:041960) Shareholder Ownership Skewed Towards Insiders?
Jan 22
Komipharm International (KOSDAQ:041960) Is Carrying A Fair Bit Of Debt
Dec 18Revenue & Expenses Breakdown
How Komipharm International makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 54,531 | 11,340 | 11,495 | 3,234 |
| 30 Jun 24 | 51,378 | 3,433 | 11,637 | 3,423 |
| 31 Mar 24 | 45,616 | -2,384 | 11,553 | 4,766 |
| 31 Dec 23 | 42,647 | -3,979 | 10,937 | 5,945 |
| 30 Sep 23 | 41,478 | -9,507 | 10,609 | 5,355 |
| 30 Jun 23 | 41,736 | -9,075 | 10,478 | 5,548 |
| 31 Mar 23 | 39,917 | -7,242 | 10,172 | 3,655 |
| 31 Dec 22 | 39,801 | -6,514 | 10,420 | 2,536 |
| 30 Sep 22 | 39,803 | -2,083 | 10,010 | 3,688 |
| 30 Jun 22 | 38,405 | -3,540 | 10,029 | 4,353 |
| 31 Mar 22 | 36,353 | -5,516 | 9,714 | 4,650 |
| 31 Dec 21 | 35,847 | -4,459 | 9,402 | 5,117 |
| 30 Sep 21 | 35,632 | -4,293 | 9,579 | 4,760 |
| 30 Jun 21 | 36,223 | -2,829 | 9,755 | 3,382 |
| 31 Mar 21 | 37,610 | -1,006 | 9,994 | 3,658 |
| 31 Dec 20 | 37,160 | -2,816 | 10,188 | 3,266 |
| 30 Sep 20 | 37,675 | -21,363 | 10,221 | 5,806 |
| 30 Jun 20 | 37,907 | -21,040 | 10,111 | 6,286 |
| 31 Mar 20 | 36,423 | -22,231 | 10,279 | 4,828 |
| 31 Dec 19 | 35,490 | -21,363 | 10,097 | 4,649 |
| 30 Sep 19 | 34,108 | -12,369 | 11,531 | 1,286 |
| 30 Jun 19 | 34,315 | -12,756 | 11,263 | 1,810 |
| 31 Mar 19 | 35,406 | -12,898 | 10,869 | 2,911 |
| 31 Dec 18 | 34,994 | -14,303 | 11,067 | 2,756 |
| 30 Sep 18 | 35,202 | -7,916 | 9,693 | 2,193 |
| 30 Jun 18 | 35,721 | -6,775 | 10,028 | 1,157 |
| 31 Mar 18 | 34,805 | -6,412 | 10,003 | 197 |
| 31 Dec 17 | 36,641 | -5,096 | 9,651 | 41 |
| 30 Sep 17 | 37,917 | 4 | 9,226 | 124 |
| 30 Jun 17 | 37,387 | -854 | 8,429 | 147 |
| 31 Mar 17 | 38,041 | -497 | 8,300 | 162 |
| 31 Dec 16 | 37,636 | 289 | 8,177 | 152 |
| 30 Sep 16 | 38,720 | -3,474 | 8,638 | 70 |
| 30 Jun 16 | 38,181 | -5,460 | 9,404 | 47 |
| 31 Mar 16 | 37,153 | -5,044 | 9,539 | 42 |
| 31 Dec 15 | 36,405 | -6,548 | 9,556 | 51 |
| 30 Sep 15 | 35,482 | -4,839 | 9,790 | 74 |
| 30 Jun 15 | 36,040 | -2,027 | 9,684 | 74 |
| 31 Mar 15 | 34,688 | -3,071 | 9,828 | 88 |
| 31 Dec 14 | 34,454 | -2,150 | 9,625 | 118 |
| 30 Sep 14 | 31,850 | 360 | 8,769 | 106 |
| 30 Jun 14 | 30,693 | -244 | 8,392 | 106 |
| 31 Mar 14 | 28,905 | -910 | 7,890 | 135 |
| 31 Dec 13 | 26,465 | -82 | 7,571 | 149 |
Quality Earnings: A041960 has a large one-off gain of ₩9.3B impacting its last 12 months of financial results to 30th September, 2024.
Growing Profit Margin: A041960 became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A041960 has become profitable over the past 5 years, growing earnings by 45.7% per year.
Accelerating Growth: A041960 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: A041960 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (21.6%).
Return on Equity
High ROE: A041960's Return on Equity (18.3%) is considered low.